Analyst Serge Belanger from Needham maintained a Buy rating on Liquidia Technologies and increased the price target to $36.00 from $32.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Serge Belanger has given his Buy rating due to a combination of factors that highlight the promising outlook for Liquidia Technologies. The company’s second-quarter earnings for 2025 showcased a robust start for Yutrepia, with sales figures exceeding initial expectations. This strong performance was marked by impressive prescription numbers and treatment initiations, indicating a positive reception in the market.
Furthermore, the early success of Yutrepia is attributed to its unique profile, which offers improved tolerability and higher dosage levels, setting it apart as a leading option in its class. As awareness and insurance coverage expand in the latter half of the year, sales growth is expected to accelerate. These factors have led to an increased price target, reflecting the anticipated continued success of Yutrepia.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $54.00 price target.